Ratings changes for Ulta Beauty, Autodesk, Autodesk, Marvell Technology and more...

August 28th, 2026

Unsubscribe
 
 
MarketBeat Daily RatingsMy Portfolio
Text "MarketBeat" to  68285 for free, real-time alerts on your watchlist stocks.  Get Free Alerts

Today's Top Stories

Permian Resources Rally Faces a Test

Permian Resources Rally Faces a Test

By Peter Frank

Strategy’s $1.59B Gamble: Checkmate at $80K?

Strategy’s $1.59B Gamble: Checkmate at $80K?

By Jeffrey Neal Johnson

Semtech Stock Rallies on Strong Q2 Results and Raised Guidance

Semtech Stock Rallies on Strong Q2 Results and Raised Guidance

By Thomas Hughes

What Is Trump’s New Dollar?

Sponsored · Partner Content

What Trump's New Dollar Could Mean for Your Money

A new executive order, 14241, could reshape how every American uses money for gas, groceries, and medical bills. Porter Stansberry compares it to Nixon's 1970s dollar reset, which minted an average of 1,300 new millionaires a day for decades - while others fell behind.

Watch Porter Stansberry's documentary to prepare your finances now.tc pixel
Trump’s Final Dollar Gambit

Sponsored · Partner Content

Newton’s Secret Law of Money

More than 300 years ago, Britain's currency was in crisis, with one in ten coins believed to be counterfeit. Sir Isaac Newton was called in to lead the Great Recoinage, restoring trust in British money and reshaping the nation's financial future. Now a similar reset may be underway at the heart of the U.S. dollar. President Trump is reportedly rebuilding the monetary order beneath the dollar for the first time in 52 years…

See the full research on the dollar reset nowtc pixel
NNVC: Major Biotech Catalyst!

Sponsored · Partner Content

NNVC Clears Phase II Ebola Trial Approval in the DRC

NanoViricides (NYSE: NNVC) just received ACOREP approval to begin a Phase II trial of NV-387 Oral Gummies for Ebola in the DRC, where the outbreak has reached 4,141 confirmed cases and 1,889 deaths as of August 6, 2026. The drug product is already in-country from prior MPox preparations, and a CRO team is assembled, potentially shortening the path to first dosing…

See why NNVC's Ebola trial approval could be a key catalysttc pixel
BSEM Is Scaling Into a Bigger MedTech Player

Sponsored · Partner Content

BioStem Technologies Lands on Nasdaq With Expanding Hospital Reach

BioStem Technologies (NASDAQ: BSEM) has completed its Nasdaq debut, marking a new chapter for its regenerative medicine platform. Hospital revenue made up roughly 87% of Q1 revenue, and the direct sales force grew from 18 to 35 reps in a single quarter following the BioTissue acquisition, which added the Neox and Clarix portfolios. A peer-reviewed randomized trial found a 53% probability of complete wound closure with BioREtain allografts versus 31% for standard of care…

Discover how BSEM is building its next regenerative medicine chapter.tc pixel
The Idea Engine™

Fresh stock ideas every week

The Idea Engine™ uses news and technical signals to surface new stock ideas every week, sent straight to your inbox with MarketBeat All Access.

Get MarketBeat All Access

More Stories

Alphabet Is Building a Base—Could a Breakout Be Next?

Alphabet Is Building a Base—Could a Breakout Be Next?

By Ryan Hasson

NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is

NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is

By Thomas Hughes

This Will Change Everything. Get Ready For the Global Power Reset.

This Will Change Everything. Get Ready For the Global Power Reset.

Just Updated

The Stock Screeners Just Got Better

We rebuilt MarketBeat's stock screeners with faster filtering across 75+ criteria to help you find your next investment idea. Take the new experience for a spin.

Try the New Screeners
Thank you for subscribing to MarketBeat!
MarketBeat empowers individual investors to make better financial decisions by delivering up-to-the-minute financial information and independent investment analysis.
 
If you need assistance with your account, please don't hesitate to email MarketBeat's South Dakota based support team at contact@marketbeat.com.
 
If you wish to opt out or change which emails you subscribe to, you can manage your email preferences or unsubscribe from this newsletter.
 
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl. #620, Sioux Falls, S.D. 57103. United States of America..
 
Today's Featured Content: Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press)